Clinical Study on the Safety and Efficacy of BRL-101 in the Treatment of Sickle Cell Disease - Trial NCT06287086
Access comprehensive clinical trial information for NCT06287086 through Pure Global AI's free database. This phase not specified trial is sponsored by Bioray Laboratories and is currently Not yet recruiting. The study focuses on Sickle Cell Disease. Target enrollment is 1 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
BRL-101 autologous hematopoietic stem and progenitor cells injection
Interventional
drug
Sponsor & Location
Bioray Laboratories
Timeline & Enrollment
N/A
May 14, 2024
Jun 10, 2026
Primary Outcome
Proportion of stem cell engrafted subjects,Time to neutrophil engraftment,Frequency, severity, and relationship to BRL-101 of adverse events over 12 months following BRL-101 infusion..
Summary
This is a single center, non-randomized, open label, single-dose study in subjects with
 Sickle Cell Disease (SCD). The study will evaluate the safety and efficacy of autologous
 CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (BRL-101)
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06287086
Non-Device Trial